Patent ID: 8580252
Filing Date: 2013-11-12
Classification: A61K,A61P,C12N,C12Y

Abstract:
1. A pharmaceutical composition, comprising: a) a soluble neutral active human hyaluronidase glycoprotein (sHASEGP), wherein: the hyaluronidase glycoprotein is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide does not comprise the complete sequence of amino acids set forth in SEQ ID NO:1; and the hyaluronidase polypeptide consists of: b) an anti-cancer agent selected from among Alemtuzumab, Bevacizumab, Docetaxel, Gemcitabine, Ibritumomab tiuxetan, Ortataxel, Paclitaxel, Rituximab, Tositumomab and Trastuzumab.